Drug treatment for melanoma: Progress, but who pays?

Medical Journal of Australia

Volumn 197, Issue 4, 2012, Pages 198-199

  Kefford, Richard F ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MELANOMA INSTITUTE AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DABRAFENIB; IPILIMUMAB; TRAMETINIB; TUMOR MARKER; VEMURAFENIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; SULFONAMIDE;

BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; EDITORIAL; HUMAN; IMMUNOLOGICAL TOLERANCE; LIFE EXTENSION; LYMPH NODE METASTASIS; MELANOMA; METASTATIC MELANOMA; MOLECULAR MODEL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; REIMBURSEMENT; RISK ASSESSMENT; RISK FACTOR; SURVIVAL TIME; TREATMENT DURATION; AUSTRALIA; ECONOMICS; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; PUBLIC HEALTH;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUSTRALIA; DRUG COSTS; FINANCING, GOVERNMENT; HEALTH POLICY; HUMANS; INDOLES; MELANOMA; NATIONAL HEALTH PROGRAMS; SULFONAMIDES;

EID: 84867631444     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja12.10955     Document Type: Editorial

References (9)

1. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005; 365: 687-701.
2. Australian Institute of Health and Welfare. Australian cancer incidence and mortality (ACIM) books. Melanoma of the skin. Canberra: AIHW, 2011. http://www.aihw.gov.au/acim-books/(accessed Jul 2012).
3. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
4. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
5. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
6. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467: 596-599.
7. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819.
8. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379: 1893-1901.
9. Weber JS, Flaherty KT, Infante JR, et al. Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFinaive metastatic melanoma. 2012 ASCO Meeting Abstracts. J Clin Oncol 2012; 30 (15 Suppl): 8510. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview= abst_detail_view&confID=114&abstractID=97785 (accessed Jul 2012).